

Claves y oportunidades de financiación europea de I+I en salud

16 de diciembre de 2025
CaixaForum València



Horizonte Europa – Convocatorias en ámbito de Salud (Clúster Salud, Misión Cáncer, Partenariados)



Jane Moreno

Servicio de Fomento de Redes y Centros de Excelencia -
Dirección General de Investigación e Innovación, GVA



HORIZONTE EUROPA-PILAR 2

Pilar 1
Excelencia científica

Consejo Europeo de Investigación (ERC)

Acciones Marie Skłodowska-Curie (MSCA)

Infraestructuras de Investigación

Pilar 2
Desafíos mundiales y competitividad industrial europea

Clústeres

- Salud
- Cultura, creatividad y sociedad inclusiva
- Seguridad civil para la sociedad
- Mundo digital, industria y espacio
- Clima, energía y movilidad
- Alimentación, bioeconomía, recursos naturales, agricultura y medio ambiente

Centro Común de Investigación (JRC)

Pilar 3
Europa innovadora

Consejo Europeo de Innovación (EIC)

Ecosistemas europeos de innovación

Instituto Europeo de Innovación y Tecnología (EIT)

Ampliar la participación y reforzar el Espacio Europeo de Investigación

Ampliar la participación y difundir la excelencia

Reformar y mejorar el sistema europeo de I+I

HORIZONTE EUROPA-PILAR 2

❖ Características clave

- Enfoque **impulsado por desafíos**: los proyectos deben responder a problemas definidos por la Comisión Europea.
- No se basan en ideas libres o bottom-up.

❖ Programa de Trabajo

- Cada clúster dispone de un **Work Programme**.
- Incluye temas de convocatoria con:
 - **Alcance**
 - **Resultados esperados (impacto)**
 - **Presupuesto recomendado**

❖ Dimensión de los Proyectos

- Presupuesto típico: entre **< €1M y varios millones**

❖ Requisitos del Consorcio

- Proyectos financiados principalmente en **consorcio**:
 - Mínimo **3 entidades legales**
 - De **3 Estados miembros o Países Asociados**
 - Al menos **una de un Estado miembro de la UE**

❖ Composición del Consorcio

- Socios muy diversos:
 - Diferentes tipos de entidades y perfiles
 - Las organizaciones deben aportar las capacidades adecuadas según las tareas

HORIZONTE EUROPA - PILAR 2 - CLÚSTER 1 SALUD



PROBLEMAS DE SALUD NUEVOS O PERSISTENTES

Amenazas para los ciudadanos y la salud pública

Sostenibilidad de los sistemas sociales y de atención de la salud

Competitividad EU de la industria de la salud y la atención sanitaria

Desafíos complejos, interrelacionados y globales

CONTEXTO POLÍTICO

Una UE climáticamente neutra y verde, apta para la era digital y una Unión Europea de la Salud

GREEN



DIGITAL



HEALTH



... de acuerdo con los
**Objetivos de Desarrollo
Sostenible** de la ONU



Iniciativas destacadas



European Health Union

Una estrategia farmacéutica para Europa

Medidas de preparación y respuesta ante las crisis

Autoridad Europea de Preparación y Respuesta ante Emergencias Sanitarias (HERA)

Plan Europeo de Lucha contra el Cáncer

Espacio Europeo de Datos Sanitarios (EEDS)

Estrategia Global de Salud de la UE

Un enfoque global de la salud mental

HORIZONTE EUROPA - PILAR 2 – CLÚSTER 1 SALUD

OBJETIVOS PRINCIPALES



Mejorar y proteger la salud y el bienestar de los ciudadanos de todas las edades mediante la generación de conocimiento y el desarrollo de soluciones innovadoras para prevenir, diagnosticar, monitorizar, tratar y curar enfermedades.



Desarrollar tecnologías sanitarias, mitigar los riesgos para la salud, proteger a la población.



Conseguir sistemas de salud pública sean más rentables, equitativos y sostenibles; Prevenir y abordar las enfermedades relacionadas con la pobreza. Apoyar y facilitar la participación y la autogestión de los pacientes.

HORIZONTE EUROPA - PILAR 2 – CLÚSTER 1 SALUD

CÓMO ALCANZAR LOS OBJETIVOS



Descubrimiento, investigación clínica, traslacional, epidemiológica, ética, ambiental y socioeconómica, así como ciencias regulatorias.



Colaboración estratégica a nivel UE e internacional. Participación de todos aquellos que puedan aportar soluciones.



Aproximación multidisciplinar, fomentando la colaboración con usuarios finales y ciudadanos.

HORIZONTE EUROPA - PILAR 2 – CLÚSTER 1 SALUD

AREAS DE INTERVENCION



**Salud a lo largo
de la vida**



**Determinantes
ambientales y
sociales**



**Enfermedades
no transmisibles
y raras**



**Enfermedades
infecciosas**



**Tecnologías y
soluciones
digitales**



**Sistemas de
atención sanitaria**

HORIZONTE EUROPA - PILAR 2 – CLÚSTER 1 SALUD

WORK PROGRAMME

DIRECTORATE-GENERAL | RTD

Research and Innovation

This Commission department is responsible for EU policy on research, science and innovation, with a view to help create growth and jobs and tackle our biggest societal challenges.

DIRECTORATE-GENERAL | SANTE

Health and Food Safety

This Commission department is responsible for EU policy on food safety and health and for monitoring the implementation of related laws.

DIRECTORATE-GENERAL | Connect

Communications Networks, Content and Technology

Connect develops and implements policies to make Europe fit for the digital age

DIRECTORATE-GENERAL | HERA

Health Emergency Preparedness and Response Authority

HERA anticipates threats and potential health crises, through intelligence gathering and building the necessary response capacities.

European Health and Digital Executive Agency (HaDEA)



Associated countries to Horizon Europe

Albania	Armenia	Bosnia and Herzegovina
Canada	Faroe Islands	Georgia
Iceland	Israel	Kosovo
Moldova	Montenegro	New Zealand
North Macedonia	Norway	Serbia
Turkey	Tunisia	Ukraine
United Kingdom		


CO-CREATION

Comité Cluster 1 Salud: Co-preside Comisión Europea + Estados miembros (27) + Países asociados

EJECUCIÓN

HORIZONTE EUROPA - PILAR 2 – CLÚSTER 1 SALUD


VÍAS DE IMPLEMENTACIÓN



HORIZONTE EUROPA - PILAR 2 – CLÚSTER 1 SALUD



Participar en
proyectos e iniciativas
europeas



HORIZONTE EUROPA - PILAR 2 – CLÚSTER 1 SALUD

WP 2026-2027 - IMPACTOS ESPERADOS = DESTINATIONS



EN

Horizon Europe

Work Programme 2026-2027

4. Health

(European Commission Decision C(2025) 8493 of 11 December 2025)

- ✓ Mayor prevención y bienestar.
- ✓ Sistemas sanitarios resilientes.
- ✓ Integración de tecnologías innovadoras.
- ✓ Liderazgo europeo en investigación.

1. Staying healthy in a rapidly changing society


2. Living and working in a health - promoting environment

3. Tackling diseases and reducing disease burden

4. Ensuring equal access to innovative, sustainable and high-quality healthcare

5. Developing and using new tools, technologies and digital solutions for a healthy society

6. Maintaining an innovative, sustainable and competitive EU health industry



2026

- 18 topics de una sola fase
 - Apertura: 10 febrero 2026
 - Fecha límite: **16 abril 2026**

2027


- 10 topics de una sola fase
 - Apertura: 10 febrero 2027
 - Fecha límite: 13 abril 2027
- 4 topics de dos fases
 - Apertura: 10 febrero 2027
 - Fecha límite:
 - (I) 13 abril 2027
 - (II) 22 septiembre 2027
- 3 topics de una sola fase
 - Apertura: 3 junio 2027
 - Fecha límite: 22 septiembre 2027

Novedades 2026

- Cambios en la plantilla de propuesta(reducción del número de páginas).
- Topic *follow-up funding*
- Restricción a la participación de entidades establecidas en China en RIAs y IAs
- Condiciones especiales de algunos topics: “the granting authority's ability to object to a transfer of ownership or to exclusive licensing of results up to 4 years after the end of the action, as outlined in Annex 5”.

¿Qué se espera financiar?

- Dar solución a necesidades europeas mediante proyectos colaborativos con un **enfoque interdisciplinar**.
- Tipos de actividades financierables: investigación básica y traslacional, investigación clínica, investigación de implementación, investigación epidemiológica, ética, regulatoria, ambiental y socioeconómica + Innovación.
- **Ensayos clínicos (financiables)**
- Proyectos competitivos, innovadores y ambiciosos(basados en excelencia, impacto e implementación).
- Foco en el impacto y la contribución a políticas europeas.
- Pacientes y ciudadanos en el centro e involucración de usuarios finales.
- Aspectos transversales: ciencia abierta, sexo y género en la investigación, SSH.



¿Quién puede participar?

- Proyectos colaborativos - Composición del consorcio: Regla 3 - 3
 - Mínimo 3 entidades legales independientes de 3 Estados Miembros (EEMM) o Países Asociados.
 - Al menos 1 EEMM.

¿Quién puede recibir financiación?

- Estados Miembros (EEMM).
- Países Asociados (ej. Noruega, Reino Unido, Canadá, Suiza... y Corea del Sur, primer país asiático en asociarse en 2025).
- Terceros países con ingresos bajo-medio.
- Otros países previstos en la convocatoria (ej. EE. UU.).
- Otros países con participación esencial (evaluación caso a caso).
- Algunos países disponen de mecanismos de financiación complementaria para la participación de terceros países en Horizon Europe.



TOPIC	€ total	€ / prop.	Nº prop.	RIA / IA / CSA	LS / AC
HORIZON-HLTH-2026-01-STAYHLTH-02: Behavioural interventions as primary prevention for Non-Communicable Diseases (NCDs) among young people	20,60 M€	9–10 M€	2	RIA	AC
HORIZON-HLTH-2026-01-STAYHLTH-03: Building public trust and outreach in the life sciences	1,9 M€	1,5–1,9 M€	1	CSA	LS
HORIZON-HLTH-2026-01-ENVHLTH-01: Towards a better understanding and anticipation of the impacts of climate change on health	55 M€	7–8 M€	7	RIA	LS
HORIZON-HLTH-2026-01-ENVHLTH-04: Towards climate resilient, prepared and carbon neutral populations and healthcare systems	45 M€	7–8 M€	6	RIA	LS
HORIZON-HLTH-2026-01-ENVHLTH-05: Support for a multilateral initiative on climate change and health research	3 M€	3 M€	1	CSA	AC
HORIZON-HLTH-2026-01-DISEASE-02: Innovative interventions to prevent the harmful effects of using digital technologies on the mental health of children and young adults	44,20 M€	8 M€	6	RIA	AC
HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions	39,30 M€	6–8 M€	5	RIA	LS
HORIZON-HLTH-2026-01-DISEASE-04: Development of novel vaccines for viral pathogens with epidemic potential	44,20 M€	9–11 M€	5	RIA	AC
HORIZON-HLTH-2026-01-DISEASE-09: Multisectoral approach to tackle chronic non-communicable diseases: implementation research maximising collaboration and coordination with sectors and in settings beyond the healthcare system (GACD)	9,8 M€	3–4 M€	3	RIA	LS
HORIZON-HLTH-2026-01-DISEASE-11: Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways	39,3 M€	6–7 M€	6	RIA	LS
HORIZON-HLTH-2026-01-DISEASE-15: Scaling up innovation in cardiovascular health	1,9 M€	1,9 M€	1	CSA	LS
HORIZON-HLTH-2026-01-CARE-01: Public procurement of innovative solutions for improving citizens' access to healthcare through integrated or personalised approaches	24,5 M€	3–8 M€	4	PPI	AC
HORIZON-HLTH-2026-01-CARE-03: Identifying and addressing low-value care in health and care systems	38 M€	10 M€	4	RIA	AC
HORIZON-HLTH-2026-01-TOOL-05: Pilot actions for follow-on funding: Leveraging EU-funded collaborative research in regenerative medicine	29,5 M€	6–8 M€	4	IA	LS
HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices	2,9 M€	2,9 M€	1	CSA	LS
HORIZON-HLTH-2026-01-TOOL-07: Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)	3,9 M€	3,9 M€	1	CSA	LS
HORIZON-HLTH-2026-01-IND-03: Regulatory science to support translational development of patient-centred health technologies	19,6 M€	4–6 M€	4	RIA	LS

STAYHLTH

HORIZON-HLTH-2026-01-STAYHLTH-02:
Behavioural interventions as primary prevention for Non-Communicable Diseases (NCDs) among young people

RIA, 9-10 M€

- Intervenciones conductuales
- Investigación de implementación
- Juventud (12–25 años)
- Top Enfermedades no transmisibles (exc cáncer)
- Hábitos saludables
- Autogestión / empoderamiento
- Herramientas digitales

HORIZON-HLTH-2026-01-STAYHLTH-03:
Building public trust and outreach in the life sciences

CSA, 1,5-1,9 M€

- Innovación en ciencias de la vida
- Comunicación científica
- Compromiso público con la ciencia
- Desinformación / Misinformación
- Procesos participativos
- Capacitación y formación


HORIZON-HLTH-2026-01-STAYHLTH-02: Behavioural interventions as primary prevention for Non-Communicable Diseases (NCDs) among young people

Call: Cluster 1 - Health (Single stage - 2026)

Specific conditions

Expected EU contribution per project

The Commission estimates that an EU contribution of between EUR 9.00 and 10.00 million would allow these outcomes to be addressed appropriately. Nonetheless, this does not preclude submission and selection of a proposal requesting different amounts.



Scope: The topic is focused on behavioural interventions for youth, defined as 12 to 25 years old, for the primary prevention of the top NCDs later in life, where “top NCDs” refers to the most prevalent NCDs⁶⁰. For the purpose of this call, NCDs explicitly exclude cancer.

Implementation research should be conducted to implement existing behavioural interventions. These interventions should be evidence-based and have an emphasis on empowerment and self-management (e.g. health literacy, health education, health promotion). As self-monitoring is an essential element of self-management, proposals should include user-friendly hardware and software for efficient self-monitoring (i.e. wearables and point-of-care devices for measuring various physiological parameters and other predictors and other biomarkers and the corresponding apps for easy readout and tracking, possibly also including gamification elements). Hardware and software should be interoperable in line with internationally accepted standards in order to avoid lock-in effects and assure scalability.

Proposals should also include most of the following aspects:

- Ensure that gender-sensitive and intersectional approaches are integrated, addressing potential gender-specific barriers for groups at risk of discrimination, as well as cultural and socioeconomic backgrounds, and should also outline how digital tools, including AI and RWD and biomarkers (e.g. genomic data, wearables, etc.) or existing relevant administrative dataset, will be integrated to enhance the scalability, personalisation, and effectiveness of interventions in the long-term.
- Present a clear, evidence-based strategy showing how the interventions will be tailored, deployed, and assessed at individual, family, community, and societal levels, while considering social inequalities and lifestyle factors (i.e. nutrition, sleep rhythm) and ensuring a robust methodological framework for evaluating the effectiveness of interventions (e.g. randomised controlled trials, quasi-experimental designs, etc.), with clearly defined indicators of success of the intervention (e.g. biometric markers, psychosocial wellbeing metrics, physical activity change, etc.). Applicants should evaluate unintended consequences for all interventions.
- Include formats that will increase collaboration between healthcare professionals, educators, families, and policymakers in promoting preventive health and should include plans for longer-term follow-up to estimate health impact and cost savings over time. Related to this, applicants should outline how policy changes related to the intervention (e.g. school meal programmes, safe urban infrastructure for exercise, digital literacy campaigns, circadian alignment, stress reduction strategies) can reinforce and scale up successful behavioural interventions, whilst taking into account how they can be replicated or adapted to different cultural, geographic and socio-economic contexts. As such, active involvement of key stakeholders throughout the study is strongly encouraged.

ENVHLTH

HORIZON-HLTH-2026-01-ENVHLTH-01:
**Towards a better understanding and anticipation
of the impacts of climate change on health**

RIA, 7-8 M€

- Cambio climático y determinantes de salud
- Portfolio: NCD y seguridad individual/ Salud mental / Enfermedades infecciosas
- Prevención y reducción de impactos climáticos
- Enfoque One Health

HORIZON-HLTH-2026-01-ENVHLTH-04:
**Towards climate resilient, prepared and carbon
neutral populations and healthcare systems**

RIA, 7-8 M€

- Cambio climático y sistemas sanitarios
- Mitigación y adaptación climática
- Tecnologías médicas bajas en carbono y soluciones digitales
- Reducción de emisiones gas efecto invernadero (GHG) y contaminantes



Call: Cluster 1 - Health (Single stage - 2026)


Specific conditions

Expected EU contribution per project

The Commission estimates that an EU contribution of between EUR 7.00 and 8.00 million would allow these outcomes to be addressed appropriately. Nonetheless, this does not preclude submission and selection of a proposal requesting different amounts.

All proposals involving the development, use and/or deployment of AI based system/technique should ensure that the proposed AI system/technique is technical robust, safe and must describe how they will uphold the principles of human agency and oversight, fairness, diversity, non-discrimination, societal and environmental well-being, transparency and accountability.

- ✓ Increase the understanding of **correlations, causal pathways and mechanistic effects between climate change and disease/health outcomes...**
- ✓ **International cooperation**, in particular with LMICs, is strongly encouraged.



Scope: The climate crisis poses an existential challenge to planetary and human health with larger effects on populations, groups and regions in a vulnerable situation. Climate change increases the incidence of non-communicable diseases and the prevalence of mental health conditions and facilitates the emergence and spread of infectious diseases. Climate change can act as a risk multiplier and exacerbates existing health conditions and vulnerabilities.

Applicants should explicitly state in their proposal which of the following broad focus areas is targeted and the proposed work should address only this specific broad focus area:

- i. Non-Communicable Diseases (NCDs) and/or individual safety (e.g. injuries or fatalities), excluding mental health aspects: proposals should explore evidence on the complex interactions between climate change (e.g. changes in the frequency and intensity of extreme weather events) and NCDs and individual safety, which often involve multiple climate exposure pathways and compound and cascading climatic events.
- ii. Mental health, considering interactions with brain health if relevant: in the broad focus area of mental health and psychosocial well-being, proposals should increase the evidence on the acute and long-term impacts of climate change and the understanding of new syndromes related to climate stress.
- iii. Infectious diseases, including vector-borne and non-vector-borne: proposals should increase the understanding of the factors driving climate-related burden from infectious diseases.

WP 2026-2027

HEALTH

HE - PILAR 2 – CLÚSTER 1 SALUD

HORIZON-HLTH-2026-01-DISEASE-02:
Innovative interventions to prevent the harmful
effects of using digital technologies on the
mental health of children and young adults

RIA, 8 M€

- Niños y adolescentes
- Trastornos mentales (ej. adicción, ansiedad, conducta autolesiva)
- Tecnologías digitales y bienestar psicológico
- Impacto de la tecnología
- Evidencia neuro-biológica y cognitiva
- Intervenciones digitales innovadoras

HORIZON-HLTH-2026-01-DISEASE-04:
Development of novel vaccines for viral
pathogens with epidemic potential

RIA, 9-11M€

- Vacunas profilácticas y terapéuticas
- Portfolio: Junin, Lassa, Andes, Hantaan, Sin Nombre, Hendra, Enterovirus D68, Venezuelan equine encephalitis
- In vitro, in vivo, FTIH-CT
- Factores biológicos y sociales
- Producción GMP

HORIZON-HLTH-2026-01-DISEASE-11:
Understanding of sex and/or gender-specific
mechanisms of cardiovascular diseases:
determinants, risk factors and pathways

RIA, 6-7 M€

- Enfermedades cardiovasculares (CVDs)
- Factores de riesgo específicos por sexo/género
- Diferencias hormonales, genéticas y fisiológicas
- Enfoque multidisciplinar: biología, epidemiología, nutrición,...

HORIZON-HLTH-2026-01-DISEASE-03:
Advancing research on the prevention,
diagnosis, and management of post-infection
long-term conditions

RIA, 6-8 M€

DISEASE

- Síndromes post-infecciosos (virus, bacteria, parásitos y hongos)
- Factores de riesgo y estrategias de prevención
- Diagnóstico y tratamiento
- Rehabilitación
- Enfoque multidisciplinario

HORIZON-HLTH-2026-01-DISEASE-09:
Multisectoral approach to tackle chronic NCD:
implementation research maximising
collaboration and coordination with sectors and
in settings beyond the healthcare system
(GACD)

RIA, 6-8 M€

- Prevención y gestión de NCD
- Implementación de intervenciones efectivas
- "fuera del sector sanitario" (ej. colegios, trabajo, comunidades)
- LMIC y poblaciones vulnerables en HIC
- Capacity building



Evaluation the Impact of Digital Technology on Children's Mental Health and Psychological Wellbeing

Sri Haryanto ¹, Jemmy ², Helmin Rumbiak ³, Fitri Amaliyah Batubara ⁴, Eka Apriyanti ⁵

¹ Universitas Sains Al-Qur'an Jawa Tengah, Indonesia

² Universitas Budi Luhur, Indonesia

³ Universitas Cenderawasih, Indonesia

⁴ Universitas Negeri Medan, Indonesia

⁵ Universitas Patompo, Indonesia

Corresponding Author: Sri Haryanto E-mail: sriharyanto@unsiq.ac.id

Article Information:

Received Juny 28, 2024

Revised Juny 30, 2024

Accepted July 5, 2024

ABSTRACT

In the digital era, children are increasingly exposed to electronic devices such as smartphones, tablets, and computers from a young age, impacting their play, learning, and social interactions. Concerns about the potential effects on children's mental health and well-being have grown, prompting research into the psychological factors influencing technology adoption and its implications. This study employs a cross-sectional survey design to explore the relationship between digital technology usage and children's mental health. Data collected from 500 children aged 8-18 years in City X includes demographics, digital technology usage patterns, and assessments using validated scales. The findings reveal significant correlations: prolonged digital technology use correlates with increased risks of anxiety ($r = 0.35, p < 0.01$), depression ($r = 0.30, p < 0.01$), and behavioral issues ($r = 0.25, p < 0.05$) among children. The study underscores the importance of balanced and monitored technology use to mitigate adverse impacts on children's well-being. Collaborative efforts involving parents, educators, and policymakers are crucial in guiding children's technology usage to optimize benefits while safeguarding mental health. Future research aims to further understand these dynamics and develop effective strategies for promoting healthy digital habits among children.

Keywords: Children's Mental, Digital Technology, Mental Health

HORIZON-HLTH-2026-01-DISEASE-02: Innovative interventions to prevent the harmful effects of using digital technologies on the mental health of children and young adults

Call: Cluster 1 - Health (Single stage - 2026)

Specific conditions

<i>Expected EU contribution per project</i>	The Commission estimates that an EU contribution of around EUR 8.00 million would allow these outcomes to be addressed appropriately. Nonetheless, this does not preclude submission and selection of a proposal requesting different amounts.
<i>Indicative budget</i>	The total indicative budget for the topic is EUR 44.20 million.
<i>Type of Action</i>	Research and Innovation Actions



HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions

Call: Cluster 1 - Health (Single stage - 2026)

Specific conditions

Expected EU contribution per project The Commission estimates that an EU contribution of between EUR 6.00 and 8.00 million would allow these outcomes to be addressed appropriately. Nonetheless, this does not preclude submission and selection of a proposal requesting different amounts.

Indicative budget The total indicative budget for the topic is EUR 39.30 million.


Type of Action Research and Innovation Actions

Eligibility conditions The conditions are described in General Annex B. The following exceptions apply:
In recognition of the opening of the US National Institutes of Health's programmes to European researchers, any legal entity established in the




If applicable, applicants are encouraged to incorporate artificial intelligence (AI) tools and advanced computational modelling/Virtual Human Twin (VHT)-powered tools to predict disease risk and progression, ensuring these tools are developed and tested for diverse populations to minimise bias. Hardware and software should be interoperable in line with internationally accepted standard.


Viral infection



Bacterial infection



Trends in Molecular Medicine



Potential contributors and therapeutic targets:

- Accumulation of senescent cells
- Unresolved infection
- Dysbiosis
- Activated microglia and macrophages
- Cytokine and chemokine dysregulation
- Imbalance between pro-inflammation mediators and pro-resolution mediators
- Gene mutations
- Epigenetic modifications
- Lifestyle risk factors

Scope: Microbial infections can lead to long-lasting consequences on patients' quality of life, leading to long-term conditions characterised by persistent inflammation, organ damage, and impaired functional capacity, which pose a growing public health and economic challenge. These conditions are insufficiently understood, underdiagnosed, and lack effective treatments. Advancing research into their prevention, treatment and management is essential to improving patient outcomes, reducing healthcare burdens, and strengthening workforce productivity.

The topic is open to long-term conditions resulting from infections by any type of microorganism (including viruses, bacteria, parasites, and fungi), which persist after the initial infection has been resolved. Research linked to cancer is excluded as it will be covered by the Cancer Mission.

Proposals should aim to develop innovative approaches for the prevention, diagnosis, and management of post-infection conditions. Proposals should address most of the following research areas:

- Identify protective and risk factors associated with the development of post-infection conditions to inform targeted prevention strategies, by integrating relevant information such as genetics, epigenetics, immune or inflammatory responses, and/or other relevant factors.
- Increase understanding of the pathophysiology of post-infection conditions (including inflammatory aspects) to identify biomarkers and develop clinically validated diagnostic approaches for early detection, disease progression and/or treatment optimisation.
- Develop and validate preventive and/or therapeutic interventions, including targeted pharmacological treatments, repurposing of existing drugs or precision medicine approaches, through early-stage clinical trials¹⁵² that demonstrate clinical safety and efficacy.
- Identify effective supportive rehabilitation approaches, including physical therapy, cognitive interventions, and psychological support, to enhance patient recovery, mental health and quality of life and evaluate their effectiveness.
- Examine best practices for integrating post-infectious disease management into primary and specialised healthcare settings, improving coordination among healthcare professionals.

CARE

HORIZON-HLTH-2026-01-CARE-01:
Public procurement of innovative solutions for improving citizens' access to healthcare through integrated or personalised approaches

PPI (Fund rate: 50%), 24,5 M€

- Consorcio de compradores públicos o privados
- Licitación pública de soluciones innovadoras para cuidados o métodos de diagnósticos personalizados.
- Soluciones coste-efectivas para necesidades reales
- Cooperación con decisores políticos y alineación con iniciativas europeas

HORIZON-HLTH-2026-01-CARE-03:
Identifying and addressing low-value care in health and care systems

RIA, 6-7 M€

- Prácticas de bajo valor, eficiencia sanitaria
- Indicadores y metodologías para medir bajo valor
- Estrategias innovadoras para reducir LVC
- Enfoques centrados en el paciente

HORIZON-HLTH-2026-01-CARE-03: Identifying and addressing low-value care in health and care systems

Call: Cluster 1 - Health (Single stage - 2026)

Specific conditions

Expected EU contribution per project

The Commission estimates that an EU contribution of around EUR 10.00 million would allow these outcomes to be addressed appropriately. Nonetheless, this does not preclude submission and selection of a proposal requesting different amounts.

Indicative budget

The total indicative budget for the topic is EUR 38.00 million.


Type of Action

Research and Innovation Actions

Research actions should address all the following objectives:

- Develop a deeper understanding of how low-value care can be identified and measured throughout the healthcare process, including testing related indicators and producing evidence-based methodologies that enable the pursuit of improved efficiency and quality of care.
- Identify instances of overuse, misuse, underuse and unwarranted variation in specific healthcare contexts across different stages of the healthcare process. This analysis should provide actionable insights for policymakers, healthcare providers and healthcare professionals to evaluate the potential of possible strategies for reducing low-value care, allowing for more informed decision-making and improved care practices.
- Develop and/or pilot innovative strategies for effective reduction of low-value care in specific settings across the care pathway. These pilots should demonstrate scalability and transferability across diverse health and care systems in Europe.

Definition of low-value care from the Report by the Expert Group on Health Systems Performance Assessment: “*From a health system perspective, low-value care encompasses overuse, misuse and underuse of healthcare services (for example, prevention, diagnostics, treatment, medication). Overuse and/or misuse comprise the delivery of harmful, ineffective, inappropriate, or not cost-effective healthcare services. Underuse refers to healthcare services not provided or used despite being necessary. Low-value care can lead to negative consequences for patients, their caregivers, the healthcare workforce, the health system as a whole and the wider environment.*”



edited by
Pawel Lukow
Amir Muzur
Zvonika Zupanič Stavec
Florian Steger

SCHOLAR Publishing House

HORIZON-HLTH-2026-01-TOOL-03:
Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing

RIA, 5-8 M€

- Reducción del uso de animales en investigación (en áreas con modelos animales no son relevantes) y testado regulatorio
- Ensayos *in-vitro*, iPSC, organoides, Organ-on-Chip, tejidos humanos
- Sensores integrados
- VHT, IA

HORIZON-HLTH-2026-01-TOOL-05:
Pilot actions for follow-on funding: Leveraging EU-funded collaborative research in regenerative medicine

IA, 6-8 M€

- Proyecto previo colaborativo EU (incl. ERA Nets),
- Proyectos acabados máx 3 años desde fin proyecto.
- Validación preclínica
- Vía a mercado y regulatoria
- TRL 5-7
- Medicina regenerativa



HORIZON-HLTH-2026-01-TOOL-07:
Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)

CSA, 3,9 M€

- CoE: proximidad con farma, centros de investigación, infraestructuras lab-to-patient (EECC, GMP, OTRI)
- Max 10 CoE con complementariedad en ATMPs
- 3 años proyecto
- Roadmap para posicionar a Europa como líder en I+D de ATMPs en 2035
- Formación, integración stakeholders

TOOL

HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing

Call: Cluster 1 - Health (Single stage - 2026)

Specific conditions

Expected EU contribution per project

The Commission estimates that an EU contribution of between EUR 5.00 and 8.00 million would allow these outcomes to be addressed appropriately. Nonetheless, this does not preclude submission and selection of a proposal requesting different amounts.

Indicative budget

The total indicative budget for the topic is EUR 49.00 million.

Type of Action

Research and Innovation Actions


Early screening
(for example, for safety or efficacy)

Static models




2D culture, transwells, co-cultures,
and 3D spheroids or organoids

Static MPS models



3D cultures with engineered features
(such as integrated contractility
readouts or electrical sensors)

Dynamic MPS models



Organ-on-chip cell cultures or interlinked
chips that may integrate flow, stretch,
vascularization or other stimuli

Assay throughput and ease of adoption


Proposals should develop or optimise scalable and reproducible platforms based on one or more of the following:

- Advanced in-vitro assays.
- iPSC-based models, organoid or complex OoC systems derived from patients and/or healthy donors.
- Human tissues that closely replicate physiological and pathological conditions.

In order to enable real-time monitoring of physiological responses, proposals should consider integration of embedded sensors. They should also address biological diversity, reflecting variations in genetics, phenotype, age, immune status, and microbiome across the population.

Moreover, proposals may incorporate one or both of the following complementary approaches to enhance predictive power and clinical relevance:

- AI-driven predictive modelling trained on high-quality, curated, bias-minimised datasets to predict outcomes of biomedical interventions, or risk assessment.
- Virtual twin technology to simulate disease progression, responses to interventions, and support the optimisation of clinical trials.



European Virtual Human Twins (VHT) Initiative: Accelerating innovation and making personalised medicine a reality through virtual human twins

21 October 2025

Brussels

The European Commission is organising a high-level event to discuss the strategic vision for the European Virtual Human Twins (VHT) Initiative – a major step towards driving AI innovation and making personalised medicine a reality.

Launched in December 2023, the European Virtual Human Twins Initiative supports the emergence and adoption of the next generation of VHTs in health and care. It showcases the EU's commitment to advancing health data infrastructures, supercomputing capacity, and artificial intelligence, in alignment with core Commission priorities, including the [AI Continent Action Plan](#), and the Apply AI and Life Sciences Strategies.

Since the Initiative's launch, more than 90 organisations from industry, academia and research have signed the [European Virtual Human Twins Manifesto](#) – a Statement of Intent on the collaborative development of VHTs and their increased adoption across the EU.

The event will build on this momentum, bringing together leading stakeholders from across Europe – including researchers, healthcare professionals, industry innovators, policymakers, and Member State authorities – to further shape the strategic vision of the Initiative. A central focus will be on accelerating innovation and bringing VHT technologies into clinical practice.

Key discussion topics

- The role of the VHT Initiative in addressing the gaps identified in the VHT Roadmap developed by the EDITH Coordination and Support Action
- How the forthcoming advanced platform for virtual human twins can reap the benefits of, and be integrated into, the European Health Data Space and other health data infrastructures (e.g. cancer imaging)
- Key aspects for VHT solutions uptake, in particular regulatory aspects
- Challenges and opportunities for VHT foundational research

Logo of the Virtual Human Twins Initiative: picture of a woman in a circle with the map of Europe as a background and the European flag on top
European Commission


[Register here](#)

Related topics

[Creating a digital society](#)
[eHealth, Wellbeing](#)
[Research and Inno](#)
[Advanced Digital Te](#)
[Artificial intelligenc](#)

Prerequisite technologies:

- Nanotechnologies (sensors and actuators)
- Artificial intelligence (algorithms)



<https://digital-strategy.ec.europa.eu/en/events/european-virtual-human-twins-vht-initiative-accelerating-innovation-and-making-personalised>

IND

HORIZON-HLTH-2026-01-IND-03:
Regulatory science to support translational development of patient-centred health technologies

RIA, 4-6 M€

- Actualización regulatoria para acelerar adopción segura de tecnologías sanitarias innovadoras
- Generar datos y mejorar evidencia sobre seguridad y rendimiento durante ciclo de vida
- Medical devices, IVD, IA, SoHO

Cambios en el template

Reducción del número de páginas parte B (propuestas single stage y 2a fase)

- ✓ **40 páginas** RIAs y IA AC (vs 45pág)
- ✓ **45 páginas** para RIAs y IAs LUMP SUM (vs 50pág)

Reducción/simplificación de secciones

2.1 Project's pathways towards impact [e.g. 1 page vs 4 pág]

- 2.1(a) The outcomes and impacts of your project may: scientific, Economic/technological, Societal
- 2.1(b) Give an indication of the **scale and significance** of the project's contribution to the expected outcomes and impacts, should the project be successful. Provide quantified estimates where possible and meaningful.

3.1 Work plan and resources [e.g. 12 pages vs 14 pág (LS 17 pages vs 19pág) – including tables]

- Table 3.1i: 'Other costs categories' items (e.g. internally invoiced goods and services)
- Table 3.1j: 'In-kind contributions' provided by third parties



WP 2026-2027

HEALTH

Destinations

Destination - Staying healthy in a rapidly changing society

Topics under this destination are directed towards the Key Strategic Orientations "A more resilient, competitive, inclusive, and democratic Europe" and "The Digital transition" of Horizon Europe's strategic plan 2025-2027⁵⁰.

Research and Innovation supported under this destination should contribute to the following expected impact, set out in the strategic plan impact summary for the Health Cluster: "people of all ages in the EU stay healthy, resilient, and independent even as society changes fast. This will arise from healthier lifestyles and behaviour, healthier diets, healthier environments, improved evidence-informed health policies, and more effective solutions for health and well-being promotion, disease prevention and monitoring, and rehabilitation".

People's healthcare needs are different depending on their age, gender, stage of life, health status and socioeconomic background. In 2021, nearly 860,000 premature deaths across the EU⁵¹ could have been prevented with effective primary prevention and other public health measures. In addition, an estimated 135 million people in Europe live with a disability⁵², highlighting the critical need for healthcare systems that are both accessible and adaptable. This number is expected to rise due to population ageing and the increasing prevalence of chronic conditions resulting from noncommunicable diseases and injuries. It is also important to consider disabilities arising from other causes, such as war-related injuries and Post-Traumatic Stress Disorder (PTSD), which add to the complexity and diversity of healthcare needs.

Aligning with the Commission's Political Guidelines for 2024-2029⁵³, which call for stepping up work on preventive health, this destination aims to strengthen disease prevention and early detection, placing support and empowerment of individuals regarding their own health, well-being and living and working conditions at the core of future public health programmes.

Research and Innovation under this destination should help enhance the dialogue and coordination among stakeholders and policymakers, ensuring integration across different care settings for holistic health promotion and disease prevention. Funded activities should seek to leverage the wealth of data sources, including real-world health data and establish a European interconnected health data ecosystem to develop integrated and personalised health promotion and disease prevention strategies. These activities will benefit from and actively support and

enrich emerging data resources such as the European Health Data Space (EHDS)⁵⁴ and European Open Science Cloud (EOSC)⁵⁵, and contribute to the European care strategy⁵⁶ and the digital transformation of health and care in the EU⁵⁷. Since Horizon Europe's launch in 2021, this destination has addressed important issues such as obesity prevention, understanding health-to-disease transitions, life course approaches to physical and mental health, healthy ageing, digital health literacy, and Artificial Intelligence (AI) for chronic disease risk prediction.

In this Work Programme part, destination "Staying healthy in a rapidly changing society" will focus on: i) addressing disabilities through the life course to support independent living and inclusion, with an emphasis on empowering persons with disabilities and their families. This priority aligns with the EU Strategy for the Rights of Persons with Disabilities 2021-2030; and ii) developing behavioural interventions as primary prevention for Non-Communicable Diseases (NCDs), with an emphasis on promoting healthy habits and sustained behavioural change among youth. This priority aligns with the 'Healthier together' EU non-communicable diseases initiative.

To increase the impact of EU investments under Horizon Europe, the Commission encourages collaboration between EU-funded projects to foster synergies through networking, joint workshops, knowledge exchange, best practices, and joint communication activities. Synergies can be explored between projects funded under the same or different topics, Clusters or Pillars of Horizon Europe. This includes collaborations between projects funded under the Health Cluster and the 'Culture, Creativity and Inclusive Society' Cluster for complementary actions, such as promoting social inclusion, health equity (including gender equality and support for groups at risk of discrimination), and mental health initiatives in education, work, and daily life (including through culture, the arts and sports).

Expected impacts:

Proposals for topics under this destination should set out a credible pathway to contributing to staying healthy in a rapidly changing society, and more specifically to one or several of the following impacts:

- Citizens, including persons with disabilities and other groups in a vulnerable situation, adopt and maintain healthier lifestyles and behaviours, make healthier choices, and achieve, where applicable, longer healthy, independent, and active lives with a reduced burden of preventable disease throughout the life course.

⁵⁰ https://research-and-innovation.ec.europa.eu/funding/funding-opportunities/funding-programmes-and-open-calls/horizon-europe-strategic-plan_en

⁵¹ "Health at a Glance: Europe 2024", available from https://health.ec.europa.eu/state-health-eu/health-glance-europe_en

⁵² <https://www.who.int/europe/news-room/fact-sheets/items/disability> The WHO European Region comprises 53 countries, covering a vast geographical region from the Atlantic to the Pacific oceans.

⁵³ https://commission.europa.eu/about-commission/2024-2029_en

HE - PILAR 2 – CLÚSTER 1 SALUD

- Citizens are empowered to effectively manage their physical and mental health and well-being, monitor their health status, and interact with healthcare providers to optimise their well-being throughout life through improved health literacy, increased engagement in and adherence to health promotion strategies.
- Children and young people are aware and empowered to better monitor and manage their physical, social and mental health with a view to lifelong healthy lifestyles.
- Society benefits from reduced economic and health burdens due to preventable illness and premature mortality, with efficiency increased by targeting scarce resources in appropriate, cost-effective ways to areas of high social return, thereby driving improvements in health and well-being for all citizens, and specifically reducing health inequalities.

Health policies and actions for health promotion and disease prevention are knowledge-based, people-centred, personalised and thus targeted and tailored to citizens' needs, and designed to reduce health inequalities.

Legal entities established in China are not eligible to participate in both Research and Innovation Actions (RIAs) and Innovation Actions (IAs) falling under this destination. For additional information please see "Restrictions on the participation of legal entities established in China" found in the Annex B of the General Annexes of this Work Programme.

The protection of European communication networks has been identified as an important security interest of the Union and its Member States. Entities that are assessed as high-risk suppliers⁵⁸ of mobile network communication equipment (and any entities they own or control) are not eligible to participate as beneficiaries, affiliated entities and associated partners to topics identified as "subject to restrictions for the protection of European communication networks". Please refer to the Annex B of the General Annexes of this Work Programme for further details.

Proposals are invited against the following topic(s):

HORIZON-HLTH-2026-01-STAYHLTH-02: Behavioural interventions as primary prevention for Non-Communicable Diseases (NCDs) among young people

Call: Cluster 1 - Health (Single stage - 2026)	
Specific conditions	
Expected EU	The Commission estimates that an EU contribution of between EUR

⁵⁸ Entities assessed as "high-risk suppliers", are currently set out in the second report on Member States' progress in implementing the EU toolbox on 5G cybersecurity of 2023 (NIS Cooperation Group, Second report on Member States' progress in implementing the EU Toolbox on 5G Cybersecurity, June 2023) and the related Communication on the implementation of the 5G cybersecurity toolbox of 2023 (Communication from the Commission: Implementation of the 5G cybersecurity Toolbox, Brussels, 15.6.2023 C(2023) 4049 final).

Proposals are invited against the following topic(s):

HORIZON-HLTH-2026-01-STAYHLTH-02: Behavioural interventions as primary prevention for Non-Communicable Diseases (NCDs) among young people

Call: Cluster 1 - Health (Single stage - 2026)

Specific conditions

Expected EU The Commission estimates that an EU contribution of between EUR

⁵⁸ Entities assessed as "high-risk" in progress in implementing the Second report on Member State progress (Communication from the Commission on the State of Play of the EU's work on NCDs, COM(2023) 4049 final).

Horizon Europe - Work Programme 2026-2027 Health	
<i>contribution per project</i>	9.00 and 10.00 million would allow these outcomes to be addressed appropriately. Nonetheless, this does not preclude submission and selection of a proposal requesting different amounts.
<i>Indicative budget</i>	The total indicative budget for the topic is EUR 20.60 million.
<i>Type of Action</i>	Research and Innovation Actions
<i>Eligibility conditions</i>	<p>The conditions are described in General Annex B. The following exceptions apply:</p> <p>In recognition of the opening of the US National Institutes of Health's programmes to European researchers, any legal entity established in the United States of America is eligible to receive Union funding.</p> <p>If projects use satellite-based earth observation, positioning, navigation and/or related timing data and services, beneficiaries must make use of Copernicus and/or Galileo/EGNOS (other data and services may additionally be used).</p> <p>Subject to restrictions for the protection of European communication networks.</p>
<i>Award criteria</i>	<p>The criteria are described in General Annex D. The following exceptions apply:</p> <p>The thresholds for each criterion will be 4 (Excellence), 4 (Impact) and 4 (Implementation). The cumulative threshold will be 12.</p>
<i>Legal and financial set-up of the Grant Agreements</i>	<p>The rules are described in General Annex G. The following exceptions apply:</p> <p>The granting authority may, up to 4 years after the end of the action, object to a transfer of ownership or to the exclusive licensing of results, as set out in the specific provision of Annex 5.</p>

Expected Outcome: This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination "Staying healthy in a rapidly changing society". To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to most of the following expected outcomes:

- Healthcare professionals have access to behavioural interventions that can be used to establish and reinforce healthy habits and sustain behavioural changes.
- Health professionals and educators have access to evidence-based strategies to mitigate risks of Non-Communicable Diseases (NCDs) for youth, with clear metrics that can be used to assess health outcomes.
- Youth have increased individual responsibility through targeted education, digital services, including easily accessible tools for self-monitoring, and community-based

HE - PILAR 2 – CLÚSTER 1 SALUD

Horizon Europe - Work Programme 2026-2027
Health

support, stemming from increased collaboration between healthcare professionals, educators and families.

- Researchers have access to Real-World Data (RWD)⁵⁹, existing health data infrastructure and digital tools, including Artificial Intelligence (AI), which can contribute to the sustained success of behavioural health interventions.
- Policymakers at local, regional, national and EU levels have new knowledge on behavioural interventions on NCDs among youth, which they can use to improve interventions in diverse European contexts.

Scope: The topic is focused on behavioural interventions for youth, defined as 12 to 25 years old, for the primary prevention of the top NCDs later in life, where "top NCDs" refers to the most prevalent NCDs⁶⁰. For the purpose of this call, NCDs explicitly exclude cancer.

Implementation research should be conducted to implement existing behavioural interventions. These interventions should be evidence-based and have an emphasis on empowerment and self-management (e.g. health literacy, health education, health promotion). As self-monitoring is an essential element of self-management, proposals should include user-friendly hardware and software for efficient self-monitoring (i.e. wearables and point-of-care devices for measuring various physiological parameters and other predictors and other biomarkers and the corresponding apps for easy readout and tracking, possibly also including gamification elements). Hardware and software should be interoperable in line with internationally accepted standards in order to avoid lock-in effects and assure scalability.

Proposals should also include most of the following aspects:

- Ensure that gender-sensitive and intersectional approaches are integrated, addressing potential gender-specific barriers for groups at risk of discrimination, as well as cultural and socioeconomic backgrounds, and should also outline how digital tools, including AI and RWD and biomarkers (e.g. genomic data, wearables, etc.) or existing relevant administrative dataset, will be integrated to enhance the scalability, personalisation, and effectiveness of interventions in the long-term.
- Present a clear, evidence-based strategy showing how the interventions will be tailored, deployed, and assessed at individual, family, community, and societal levels, while considering social inequalities and lifestyle factors (i.e. nutrition, sleep rhythm) and ensuring a robust methodological framework for evaluating the effectiveness of interventions (e.g. randomised controlled trials, quasi-experimental designs, etc.), with clearly defined indicators of success of the intervention (e.g. biometric markers, psychosocial wellbeing metrics, physical activity change, etc.). Applicants should evaluate unintended consequences for all interventions.

⁵⁹ EMA definition: "Real-World Data are routinely collected data relating to patient health status or the delivery of healthcare from a variety of sources other than traditional clinical trials (e.g. claims databases, hospital data, electronic health records, registries, mhealth data, etc.)".

⁶⁰ The prevalence of a disease is the number of cases in a defined population at a specified point in time. See <https://iris.wto.int/bitstream/handle/10665/36838/9241544465.pdf>

WP 2026-2027
HEALTH

Horizon Europe - Work Programme 2026-2027
Health

- Include formats that will increase collaboration between healthcare professionals, educators, families, and policymakers in promoting preventive health and should include plans for longer-term follow-up to estimate health impact and cost savings over time. Related to this, applicants should outline how policy changes related to the intervention (e.g. school meal programmes, safe urban infrastructure for exercise, digital literacy campaigns, circadian alignment, stress reduction strategies) can reinforce and scale up successful behavioural interventions, whilst taking into account how they can be replicated or adapted to different cultural, geographic and socio-economic contexts. As such, active involvement of key stakeholders throughout the study is strongly encouraged.

This topic requires the effective contribution of social sciences and humanities (SSH) disciplines and the involvement of SSH experts, organisations as well as the inclusion of relevant SSH expertise, in order to produce meaningful and significant effects enhancing the societal impact of the related research activities.

The proposals should adhere to the FAIR⁶¹ data principles, adopt data quality standards, data integration operating procedures and GDPR⁶² compliant data sharing/access good practices developed by the European research infrastructures, where relevant.

Applicants should provide details of their clinical studies⁶³ in the dedicated annex using the template provided in the submission system. As proposals under this topic are expected to include clinical studies, the use of the template is strongly encouraged.

MISIONES UE



Las misiones ofrecen una solución, una oportunidad y un enfoque para abordar los numerosos retos a los que se enfrentan las personas en su vida cotidiana

- Audaces e inspiradoras, con una amplia relevancia social
- Una dirección clara: objetivos, medibles y con plazos
- Ambiciosas pero basadas en acciones de I+I realistas
- Impulsan la innovación en todas las disciplinas, sectores y actores
- Basadas en un enfoque ascendente de múltiples soluciones





MISIÓN CÁNCER



Objetivo de la Misión: Mejorar la vida de más de 3 millones de personas para 2030 mediante la prevención, la curación, y para que los afectados por el cáncer, incluidas sus familias, vivan más y mejor, junto con el Plan Europeo de Lucha contra el Cáncer.



Entender
el cáncer



Diagnóstico y
Tratamiento



Prevención y
Detección temprana



Calidad de
vida

Prioridades transversales:

Acceso equitativo para todos - Medicina personalizada – Innovación - Cáncer pediátrico



MISIÓN CÁNCER

The document cover features the European Commission logo and the title 'Europe's Beating Cancer Plan: Joining Forces' with the hashtag '#EUCancerPlan'. Below the title is a large purple box containing the word 'Conclusiones' in white. At the bottom left, it says 'COMMISSION STAFF WORKING DOCUMENT' and 'Review of Europe's Beating Cancer Plan'.

La ejecución del Plan contra el Cáncer está muy avanzada

firme compromiso con la prevención del cáncer

La gobernanza del Plan ha demostrado su eficacia

ejemplo de éxito de una iniciativa basada en la salud en todas las políticas

problemas identificados:
barreras financieras, clínicas, políticas e institucionales, de comportamiento y culturales

enfoque de las acciones en curso y futuras

cánceres pediátricos

pacientes edad avanzada

garantizar la calidad de vida

cánceres raros

personal sanitario

barreras financieras

mayor énfasis en la ejecución, el seguimiento y la evaluación



MISIÓN CÁNCER

European Missions
Cancer
Improving the lives of more than 3 million people by 2030 through prevention, cure and for those affected by cancer including their families, to live longer and better
Implementation Plan

This is an internal working document of the European Commission. Therefore the budget figures mentioned are approximate and the document will be updated. It is made public for information only and does not bind the European Commission. The European Commission is not liable for any consequence stemming from the reuse of this document.

Research and Innovation

PLAN DE IMPLEMENTACIÓN

Elementos clave para el éxito:

1. Identificar y explotar resultados I+D+I (H2020 + HE) y países → Acelerar su traslado a la salud pública y la práctica clínica.
2. Establecer agenda estratégica común de I+D+I.
3. Crear vínculo entre la I+D+I y el desarrollo de políticas.
4. Aumentar la colaboración intersectorial e involucración de los decisores.

Programa de Trabajo Horizonte Europa -> Condiciones similares convocatorias de Salud, con aspectos diferenciales.

Otros programas: EU4Health, Digital Europe, entre otros



Convocatorias 2026-2027

Impactos esperados

- ✓ Mejorar la comprensión del cáncer en el contexto del medio ambiente, el trabajo y el estilo de vida en el sentido más amplio posible;
- ✓ Potenciar las estrategias transversales de prevención, cribado y detección precoz del cáncer;
- ✓ Optimizar el diagnóstico y el tratamiento del cáncer en base al principio de acceso equitativo.
- ✓ Mejorar la calidad de vida de los pacientes con cáncer, los supervivientes y sus familias mediante un amplio análisis de todos los factores y necesidades clave relacionados con la calidad de vida;
- ✓ Acelerar la transformación digital de la investigación, la innovación y los sistemas sanitarios.

Horizon Europe

Work Programme 2026-2027

12. Missions

(European Commission Decision C(2025) 8493 of 11 December 2025)

Luchar contra el cáncer
desde todos **los frentes**



MISIÓN CÁNCER



Entender el Cáncer

Acciones sobre modelos virtuales de gemelos humanos (VHT) para avanzar en el conocimiento y la comprensión del inicio y la progresión del cáncer
Acciones sobre genómica funcional en la investigación oncológica para aumentar la comprensión del inicio y la evolución de la enfermedad.



Prevención y Detección temprana

Acciones para apoyar el desarrollo de herramientas basadas en el microbioma para la prevención del cáncer.



Diagnóstico y Tratamiento

Apoyar ensayos clínicos para cánceres raros
Acciones destinadas a mejorar los resultados en salud de los pacientes oncológicos mediante el abordaje de la economía de la salud, los sistemas sanitarios y la investigación sobre resultados en salud
Acciones para apoyar medicamentos, dispositivos médicos y tecnologías más asequibles.

WP 2026

Fecha de cierre 15 septiembre 2026

HORIZON-MISS-2026-02-CANCER-01:
Virtual Human Twin (VHT) Models for Cancer Research

RIA, 8-9 M€ prop., 4 prop.

HORIZON-MISS-2026-02-CANCER-02:
Microbiome for early cancer prediction before the onset of disease

RIA, 15M€/prop., 1 prop.

HORIZON-MISS-2026-02-CANCER-03:
Pragmatic clinical trials to optimize immunotherapeutic interventions for patients with refractory cancers

RIA, 7-8M€ prop., 3 prop.




Calidad de vida

- Apoyar la calidad de vida de los pacientes oncológicos de edad avanzada y respaldar acciones para una atención paliativa más temprana y precisa para los pacientes con cáncer.
- Una acción para apoyar a los jóvenes supervivientes de cáncer mediante el fomento de la colaboración entre financiadores nacionales y regionales y organizaciones filantrópicas.
- Una acción de innovación para seguir desarrollando el Centro Digital Europeo del Paciente Oncológico, incorporando un módulo específico para impulsar la salud mental de los jóvenes pacientes con cáncer y supervivientes, en consonancia con las ambiciones del Enfoque Integral de la UE sobre la salud mental.


- HORIZON-MISS-2026-02-CANCER-04: Earlier and more precise palliative care
RIA, 5 M€ prop., 3 prop.
- HORIZON-MISS-2026-02-CANCER-05: Boosting mental health of young cancer survivors through the European Cancer Patient Digital Centre (ECPDC)
IA, 7 M€ prop., 1 prop.
- HORIZON-MISS-2026-02-CANCER-07: Improve the Quality of Life of older cancer patients
RIA, 5-6 M€ prop., 5 prop.



MISIÓN CÁNCER



Objetivos concretos, con metas y horizonte temporal definidos



Misiones son mucho más que I+I



Imprescindible la complementariedad de fondos y sinergias para alcanzar las metas propuestas

DÓNDE ENCONTRAR INFORMACIÓN

General

The screenshot shows the European Commission's Research and Innovation website. At the top, there are links for LN and Search. Below the header, a banner features a purple ribbon and the word 'CANCER'. The main content area is titled 'EU Mission: Cancer' and includes a sub-section 'What are EU Missions?'. It also features a sidebar with links for 'PAGE CONTENTS', 'What are EU Missions?', 'An official website of the European Union', 'How do you know?', 'What is this EU Mission?', 'Funding opportunities', 'More info...', and 'Do...'. The URL in the address bar is 'https://ec.europa.eu/research/missions/cancer_en'.

Cancer Projects Tool

Implementación

The screenshot shows the European Commission's Knowledge for Policy website. At the top, there are links for Log in, Translate this page, and Search. The main content area is titled 'KNOWLEDGE FOR POLICY' and 'Supporting policy with scientific evidence'. It includes a sub-section 'Cancer projects tool' which describes it as an interactive tool to find synergies and relationships between cancer-related projects funded by Horizon Europe and EU4Health. The URL in the address bar is 'https://ec.europa.eu/knowledge-for-policy/cancer-projects-tool_en'.


The screenshot shows the European Commission's EU MISSIONS website. At the top, there is a banner for 'EU MISSIONS' with icons for a thermometer, a ribbon, a building, water, and a plant. Below the banner, it says 'Concrete solutions for our greatest challenges'. A large graphic shows a circular path with dots, labeled 'Quality of life' and 'Diagnosis & treatment'. The text 'INFO DAYS online' is prominently displayed. Below this, it says '20 y 21 de enero 2026' and 'Horizonte Europa | Misiones'. A section titled 'Infoday de Misiones Horizonte Europa, convocatorias 2026' is shown with the text '20 de Enero de 2026 - 21 de Enero de 2026' and 'Los días 20 y 21 de enero de 2026, la Comisión Europea organiza...'. At the bottom, there are search filters for 'Action area', 'Coordinator country', 'Keywords', and 'Acronym'.

DÓNDE ENCONTRAR INFORMACIÓN



Info day - Cluster 1 Health

El 10 de febrero de 2026 la Comisión Europea organiza una jornada informativa on-line sobre las convocatorias 2026 del P



Infoday y networking platform EDCTP3 2025

Info Day 2026: presentations and Q&A
Presentación del programa de trabajo 2026: topics, proceso de solicitud y criterios de evaluación Q&A Plataforma de búsqueda de socios



Cluster Health Horizon Europe Brokerage Event 2026

Del 26 al 30 de enero de 2026, la red de Puntos Nacionales de Contacto del Clúster de Salud, a través del proyecto



IHI Call Days - Call 12

La [Iniciativa de Salud Innovadora \(IHI\)](#) ha organizado los días 19 y 20 de enero los IHI Call Days en formato online

DÓNDE ENCONTRAR INFORMACIÓN



Funding & tender opportunities

Single Electronic Data Interchange Area (SEDIA)



SEARCH FUNDING & TENDERS

HOW TO PARTICIPATE

PROJECTS & RESULTS

WORK AS AN EXPERT

SUPPORT

Find calls for proposals and tenders

Search calls for proposals and tenders by keywords, programmes...

Search

EU Programmes

Asylum, Migration and
Integration Fund (AMIF)

Border Management and Visa
Instrument (BMVI)

Citizens, Equality, Rights and
Values Programme (CERV)

Connecting Europe Facility
(CEF)

Creative Europe Programme
(CREA)

Customs Control Equipment
Instrument (CCEI)

Customs Programme (CUST)

Digital Europe Programme
(DIGITAL)

Erasmus+ Programme
(ERASMUS)

European Development Fund
Programme

EU External Action (RELEX)

EU4Health Programme (EU4H)

Euratom Research and Training
Programme (EURATOM)

Europe Direct (ED)

European Defence Fund

Maritime, Fisheries
and Agriculture Fund (EMFAF)

European Parliament (EP)

European Social Fund + (ESF)

European Solidarity Corps
(ESC)

Fiscalis Programme (FISC)

Horizon Europe (HORIZON)

Information Measures for the
EU Cohesion policy (IMREG)

Innovation Fund (INNOVFUND)

Internal Security Fund (ISF)

<https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/home>



Filters

Programme [Horizon Europe \(HORIZON\)](#)

2021 - 2027

Grants

This page includes reference documents of the programmes managed on the EU Funding & Tenders portal starting with the [Horizon Europe](#) programme. It contains links to model grant agreements and guides for specific actions. Please select the programme to see the reference documents.

Procurement

Reference Documents related to tendering opportunities are available directly on the calls for tenders pages. You may search for them via the "Calls for tenders" menu.



Filter...

[HE and Euratom Work Programme on Horizontal Expenditure 2025-2026](#) >

- > Legislation
- ▽ Work programme & call documents
 - > 2021-2022
 - > 2023-2025
 - > 2025
 - ▽ 2026-2027
 - > HE Main Work Programme 2026-2027
 - > EIC Work Programme 2026
 - > ERC Work Programme 2026
 - > Grant agreements and contracts
 - > Simplified cost decisions
 - > Guidance
 - > Templates & forms
 - > Experts lists
 - > Funding & Tenders Portal

[1. General introduction](#) >[2. Marie Skłodowska-Curie Actions](#) >[3. Research Infrastructures](#) >[4. Health](#) >[5. Culture, creativity and inclusive society](#) >[6. Civil Security for Society](#) >[7. Digital, Industry and Space](#) >[8. Climate, Energy and Mobility](#) >[9. Food, Bioeconomy, Natural Resources, Agriculture and Environment](#) >[10. European Innovation Ecosystems \(EIE\)](#) >[11. Widening participation and strengthening the European Research Area](#) >[12. Missions](#) >[13. New European Bauhaus Facility](#) >[14. Horizontal Activities](#) >[15. General Annexes](#) >

[Home](#) > [Work as an expert](#)

Work as an expert

We need experts for:

- Assessing applications for EU funding (including prizes and tenders),
- Monitoring of EU funded projects and contracts,
- Giving your advice on specific issues.

Experts act in their individual capacity to assist the EU services with the implementation of EU funding & tenders managed through the Portal.

Do you have an extensive professional experience & proven domain-knowledge?

[Register as expert](#)

As new expert, you will be first requested to create your EU login account and register your profile.

Only one complete profile per expert is allowed and we have the obligation to delete duplicate profiles to ensure compliance with the applicable legal framework. You can find more guidance if you have [lost access to your account](#) or [created a duplicate profile](#).

Find out more about the evaluation and monitoring objectives and scope in the [terms of reference](#).

If you need further guidance, access the [key steps for experts](#).

Calls for expressions of interest for experts

 [Call for expressions of interest for experts \(2021-2027\)](#) [Calls for expressions of interest for experts \(2014-2020\)](#)

Useful links

[Helpdesk and Support Services](#)[FAQ for Experts](#)[Experts dashboard](#)[List of contracted experts](#)

<https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/home>

Apoyo en Salud HE

Puntos Nacionales de Contacto



Marta de Diego
CDTI
marta.dediego@cdti.es
+34 91 581 55 62



Marta Marín
FECYT, MCIN
marta.marin@fecyt.es
+34 91 425 09 09

@HorizonteEuropa
@CDTI_innovacion

www.horizonteeuropa.es
www.cdti.es



PARTENARIADOS EUROPEOS

Nueva generación de asociaciones orientadas a los objetivos y más ambiciosas, en apoyo de los objetivos acordados de las políticas de la UE.

Principales características

- Una orientación estratégica
- Una arquitectura y un conjunto de herramientas sencillos
- Un conjunto de criterios comunes para el ciclo de vida

COPROGRAMADOS

A partir de memorandos de entendimiento o acuerdos contractuales aplicados independientemente por los socios y por Horizonte Europa.

COFINANCIADOS

A partir de un programa común acordado y ejecutado por los socios; compromiso de los socios respecto de las contribuciones financieras y en especie.

INSTITUCIONALIZADOS

A partir de una dimensión a largo plazo y de la necesidad de un alto nivel de integración; asociaciones basadas en los artículos 185 y 187 del TFUE y en los actos jurídicos del EIT para el periodo 2021-2027.



PARTENARIADOS EUROPEOS

PILLAR II - Global challenges & European industrial competitiveness

PILLAR III - Innovative Europe

CLUSTER 1: Health	CLUSTER 2: Culture, Creativity, Inclusive Societies	CLUSTER 4: Digital, Industry & Space	CLUSTER 5: Climate, Energy & Mobility	CLUSTER 6: Food, Bio-economy, Agriculture, Env...	EUROPEAN INNOVATION ECOSYSTEMS
Innovative Health Initiative	Resilient Cultural Heritage*	Chips (formerly KDT)	Clean Hydrogen	Circular Bio-based Europe	Innovative SMEs
Global Health Partnership	Social Transformations and Resilience*	Smart Networks & Services	Clean Aviation	R&I in the Mediterranean Area (Art. 185)	EIT
Transformation of health systems		High Performance Computing	Single European Sky ATM Research 3	Biodiversa+	InnoEnergy
Chemicals risk assessment		European Metrology (Art. 185)	Europe's Rail	Climate Neutral, Sustainable & Productive Blue Economy	Climate
ERA for Health		AI-Data-Robotics	Connected and Automated Mobility	Water4All	Digital
Rare diseases		Photonics	Batt4EU	Animal Health & Welfare	Food
One-Health Anti Microbial Resistance		Made in Europe	Zero-emission waterborne transport	Accelerating Farming Systems Transitions	Health
Personalised Medicine		Clean steel – low-carbon steelmaking	Zero-emission road transport	Agriculture of Data	Raw Materials
Pandemic Preparedness		Processes4Planet	Built4People	Safe and Sustainable Food System	Manufacturing
Brain Health*		Global competitive space systems	Solar Photovoltaics*	Forests and Forestry for sustainable Future*	Urban Mobility
		Innovative Materials for EU*	Clean Energy Transition		Cultural and Creative Industries
		Virtual Worlds*	Driving Urban Transitions		Water, Marine and Maritime Sectors and Ecosystem*
		Textiles of the Future*			
		Raw Materials for the Green and Digital Transition*			

* Under preparation

CROSS-PILLARS I AND II

European Open Science Cloud



PARTENARIADOS EUROPEOS EN SALUD

Cofinanciados

- Partnership on Risk Assessment for chemicals (PARC)
- ERA4Health
- Transforming Health Care Systems (THCS)
- Personalised Medicine (EP PerMed)
- Rare Diseases (ERDERA)
- One Health AMR (OH AMR)
- Pandemic Preparedness (BE READY)
- Brain Health

Elaboración

- Agenda Estratégica de Investigación e Innovación(SRIA)
- Borrador de propuesta (diseño y concepto)
- Características:
 - Convocatorias cofinanciadas anuales
 - 7 años de programa (más varios años phasing-out)



PARTENARIADOS EUROPEOS COFINANCIADOS

European Partnership on Assessment of Risk of Chemicals (PARC)

El objetivo de la Asociación Europea para la Evaluación de Riesgos de los Productos Químicos (PARC) es mejorar el conocimiento sobre las sustancias químicas para proteger mejor la salud de las personas y el medio ambiente.



Fostering ERA for Health (ERA4Health)

Fomentar el EEI para la Salud (ERA4Health) es una iniciativa de amplio alcance temático en la que organizaciones financieras establecen conjuntamente programas de investigación e innovación en el ámbito de la salud. La asociación se centra en abordar enfermedades y reducir la carga de las enfermedades.



Transforming health and care systems (THCS)

Transformar los Sistemas de Salud y Atención (THCS) tiene como objetivo hacer que los sistemas de salud de Europa sean más sostenibles, eficientes, resilientes, inclusivos, innovadores y de alta calidad, así como centrados en las personas y accesibles, basados en nuevos conocimientos. Actualmente, 62 organizaciones de 25 países están trabajando juntas en THCS.





PARTENARIADOS EUROPEOS COFINANCIADOS

European Partnership for Personalised Medicine (EP PerMed)

El objetivo de la Asociación Europea para la Medicina Personalizada (EP PerMed) es la coordinación entre la UE, los estados miembros de la UE y las regiones, así como la promoción de la investigación en el ámbito de la medicina personalizada. Esto también debe garantizar una implementación más rápida de los resultados de la investigación y las innovaciones en la práctica clínica.



European Partnership on Rare Diseases (ERDERA)

La Alianza Europea de Investigación sobre Enfermedades Raras tiene como objetivo mejorar la vida de las personas que padecen enfermedades raras mediante el desarrollo de nuevos diagnósticos y tratamientos. Coordina programas de investigación e innovación a nivel europeo, nacional y local, y reunirá actividades de financiación de la investigación y de apoyo a la investigación.



European Partnership on One Health AMR (OHAMR)

La asociación tiene como objetivo coordinar actividades y financiación en el ámbito de la resistencia antimicrobiana entre la UE y los países involucrados. El objetivo es contribuir al Plan de Acción One Health de la UE contra la RAM (Resistencia Antimicrobiana) y al Plan de Acción Global de la OMS sobre la RAM.





PARTENARIADOS EUROPEOS COFINANCIADOS

European Partnership on Pandemic Preparedness

La asociación contribuirá a permitir que los Estados miembros y la Comisión Europea apoyen conjuntamente la investigación y la innovación en la preparación frente a pandemias y tendrá como objetivo mejorar la preparación de la UE para predecir, prevenir y responder a las amenazas de salud infecciosas emergentes.



European Partnership for Brain Health

El objetivo de la asociación Brain Health es mantener y promover la salud cerebral en la sociedad abordando de manera integral los desafíos biomédicos, económicos y sociales. La asociación tendrá como objetivo proporcionar soluciones innovadoras para mantener y mejorar la salud cerebral, así como prevenir, diagnosticar y tratar trastornos neurológicos y mentales en Europa y en todo el mundo.





PARTENARIADOS EUROPEOS COFINANCIADOS

Partenariados Europeos convocatorias 2026



Iniciativa	Financiación	Tema de las convocatorias
European Partnership Antimicrobial Resistance (OH AMR)	750.000 €	<i>Treatments and Adherence to Treatment protocols</i>
European Partnership Brain Health	750.000 €	<i>JTC1- Biological, social and environmental factors that impact the trajectory of brain health across the lifespan – in the field of neurological, mental and sensory disorders</i> <i>JTC2- Biological, social and environmental factors that impact the trajectory of brain health across the lifespan – in the field of neurodegeneration</i>
ERDERA	1.600.000 €	<i>Resolving unsolved cases in rare genetic and non-genetic diseases through variant validation and new technological approaches</i>
ERA4Health-Prevent-OO	600.000 €	<i>Understanding and Preventing Overweight and Obesity</i>
ERA4Health-Trials4Health	2.400.000 €	<i>Multi-country Investigator Initiated Clinical Trials in Cardiovascular, Autoimmune and Metabolic diseases</i>
European partnership on Transforming health and care systems (THCS)	1.000.000 €	<i>Inequalities in access to health and care</i>
European Partnership on Personalized Medicine (EP PerMed)	3.000.000 €	<i>Personalised Medicine for Cardiovascular, Metabolic, and Renal diseases</i>
BE READY NOW	1.000.000 €	<i>Advancing knowledge of host and pathogen dynamics to better combat emerging diseases</i>



11.100.000 €

Claves y oportunidades de financiación europea de I+I en salud



PARTENARIADOS EUROPEOS EN SALUD INSTITUCIONALIZADOS

Innovative Health Initiative Joint Undertaking (IHI JU)

Asociación público-privada entre la Unión Europea, representada por la Comisión Europea, y diversas asociaciones de la industria sanitaria: EFPIA (empresas farmacéuticas), COCIR (empresas de imagen, radioterapia, TIC y electromedicina), MedTechEurope (empresas de tecnología médica), EuropaBio (empresas de biotecnología), VaccinesEurope (empresas de vacunas). Por lo tanto, el IHI es mucho más amplio que el IMI en términos de los sectores industriales involucrados y el enfoque en los contenidos.



Global Health EDCTP3 Joint Undertaking

Global Health European & Developing Countries Clinical Trials Partnership (EDCTP3) es una asociación entre la Comisión Europea, que representa a la Unión Europea, y la Asociación EDCTP, que representa a los gobiernos de 15 países europeos y 30 países de África subsahariana. Su objetivo es apoyar asociaciones internacionales de investigación que aceleren la evaluación clínica de medicamentos, vacunas y diagnósticos para las enfermedades infecciosas más importantes en África subsahariana. También busca promover enfoques novedosos para la vigilancia y el control de infecciones emergentes/recurrentes y fortalecer las capacidades de investigación clínica en África subsahariana. Basándose en los dos programas anteriores de EDCTP, la asociación garantizará que más personas tengan acceso a nuevas intervenciones médicas y ayudará a proteger la seguridad sanitaria regional y global.



Global Health
EDCTP3

[Salud Global EDCTP3](#)

€147 million available to fund
global health research and
innovation



Global Health EDCTP3
Work
Programme
2026 Published

- » Infoday (+networking platform): [5 febrero 2026](#)
- » 4 RIAs - two-stage, deadline 1st stage : [4 marzo 2026](#)
- » 2 CSAs - single-stage, deadline: [31 agosto 2026](#)



PARTENARIADOS EUROPEOS EN SALUD

MÁS INFORMACIÓN

- **Sitio web de los partenariados europeos** en europa.eu:
 - Proyectos de propuestas de partenariado
 - Informe de coherencia y sinergias
 - Infografías
- **Plan estratégico de Horizonte Europa:** identificación de partenariados coprogramados y cofinanciados

FUENTES

- [CDTI](#)
- [CDTI SOST](#)
- [FECYT](#)
- [EUROPEAN COMMISSION RESEARCH AND INNOVATION](#)
- [EU FUNDING & TENDERS PORTAL](#)
- [ERA-LEARN](#)



INFODAY
UE · SALUD



¡Gracias por
vuestra atención!

